|
|
Line 1: |
Line 1: |
| {{ Infobox immunostain | | {{ Infobox immunostain |
| | Name = {{PAGENAME}} | | | Name = {{PAGENAME}} |
| | Image = Stomach Metastatic Breast Carcinoma, IHC for Estrogen Receptor (5610737866).jpg | | | Image = |
| | Width = | | | Width = |
| | Caption = ER+ve in metastatic breast carcinoma. | | | Caption = PgR+ve in metastatic breast carcinoma. |
| | Abbrev = ER | | | Abbrev = PgR |
| | Synonyms = | | | Synonyms = |
| | Similar = | | | Similar = |
Line 11: |
Line 11: |
| | Subspecial = | | | Subspecial = |
| | Pattern = nuclear staining | | | Pattern = nuclear staining |
| | Positive = Breast and endometrial carcinoma | | | Positive = Breast carcinoma |
| | Negative = | | | Negative = |
| | Other = | | | Other = |
| }} | | }} |
|
| |
|
| '''Estrogen receptor''', abbreviated '''ER''', is a common [[immunostain]]. | | '''Progesterone receptor''', abbreviated '''PgR''', is a common [[immunostain]]. |
|
| |
|
| ==General== | | ==General== |
| *Nuclear stain - like most other "p" stains. | | *Nuclear stain. |
| *In the context of breast pathology it is a [[Quality#Classification_of_IHC_tests|class II IHC test]], as it is used for treatment decisions by itself.<ref name=pmid20154273>{{Cite journal | last1 = Torlakovic | first1 = EE. | last2 = Riddell | first2 = R. | last3 = Banerjee | first3 = D. | last4 = El-Zimaity | first4 = H. | last5 = Pilavdzic | first5 = D. | last6 = Dawe | first6 = P. | last7 = Magliocco | first7 = A. | last8 = Barnes | first8 = P. | last9 = Berendt | first9 = R. | title = Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee/Immunohistochemistry: best practice recommendations for standardization of immunohistochemistry tests. | journal = Am J Clin Pathol | volume = 133 | issue = 3 | pages = 354-65 | month = Mar | year = 2010 | doi = 10.1309/AJCPDYZ1XMF4HJWK | PMID = 20154273 }}</ref>
| | |
|
| |
|
| ==Positive== | | ==Positive== |
| *Normal breast - usually patchy staining.
| |
| *[[Florid epithelial hyperplasia of the usual type]] - usually patchy staining<ref name=Ref_BP276>{{Ref BP|276}}</ref> - see ''[[Invasive_breast_cancer#Immunostains_for_typing_and_diagnosis|immunostains for typing and diagnosis of breast lesions]]''.
| |
| *[[Breast carcinoma]] - most. | | *[[Breast carcinoma]] - most. |
| **[[Ductal carcinoma in situ]] - most, usually diffuse<ref name=Ref_BP276>{{Ref BP|276}}</ref> - see ''[[Invasive_breast_cancer#Immunostains_for_typing_and_diagnosis|immunostains for typing and diagnosis of breast lesions]]''.
| | *[[Meningeoma]] - most except for fibromatous subtype.<ref>{{Cite journal | last1 = Schnegg | first1 = JF. | last2 = Gomez | first2 = F. | last3 = LeMarchand-Beraud | first3 = T. | last4 = de Tribolet | first4 = N. | title = Presence of sex steroid hormone receptors in meningioma tissue. | journal = Surg Neurol | volume = 15 | issue = 6 | pages = 415-8 | month = Jun | year = 1981 | doi = | PMID = 7280951 }}</ref><ref>{{Cite journal | last1 = Tilzer | first1 = LL. | last2 = Plapp | first2 = FV. | last3 = Evans | first3 = JP. | last4 = Stone | first4 = D. | last5 = Alward | first5 = K. | title = Steroid receptor proteins in human meningiomas. | journal = Cancer | volume = 49 | issue = 4 | pages = 633-6 | month = Feb | year = 1982 | doi = | PMID = 7055777 }}</ref> |
| **[[Invasive lobular carcinoma]] - all.
| |
| **[[Invasive ductal carcinoma of the breast]] - most.
| |
| *[[Endometrial carcinoma]]s.
| |
| * PRL-producing [[pituitary adenoma]]s (Prolactioma)<ref>{{Cite journal | last1 = Delgrange | first1 = E. | last2 = Vasiljevic | first2 = A. | last3 = Wierinckx | first3 = A. | last4 = François | first4 = P. | last5 = Jouanneau | first5 = E. | last6 = Raverot | first6 = G. | last7 = Trouillas | first7 = J. | title = Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth. | journal = Eur J Endocrinol | volume = 172 | issue = 6 | pages = 791-801 | month = Jun | year = 2015 | doi = 10.1530/EJE-14-0990 | PMID = 25792376 }}</ref>
| |
| | |
|
| |
|
| ===Occasionally positive=== | | ===Occasionally positive=== |
| *[[Lung adenocarcinoma]] - dependent on the ER subunit target - ERα ~1%, ERβ ~79%.<ref name=pmid27069542>{{Cite journal | last1 = Tanaka | first1 = K. | last2 = Shimizu | first2 = K. | last3 = Kakegawa | first3 = S. | last4 = Ohtaki | first4 = Y. | last5 = Nagashima | first5 = T. | last6 = Kaira | first6 = K. | last7 = Horiguchi | first7 = J. | last8 = Oyama | first8 = T. | last9 = Takeyoshi | first9 = I. | title = Prognostic significance of aromatase and estrogen receptor beta expression in EGFR wild-type lung adenocarcinoma. | journal = Am J Transl Res | volume = 8 | issue = 1 | pages = 81-97 | month = | year = 2016 | doi = | PMID = 27069542 }}</ref>
| | Lung adenocarcinoma.<ref>{{Cite journal | last1 = Berardi | first1 = R. | last2 = Morgese | first2 = F. | last3 = Santinelli | first3 = A. | last4 = Onofri | first4 = A. | last5 = Biscotti | first5 = T. | last6 = Brunelli | first6 = A. | last7 = Caramanti | first7 = M. | last8 = Savini | first8 = A. | last9 = De Lisa | first9 = M. | title = Hormonal receptors in lung adenocarcinoma: expression and difference in outcome by sex. | journal = Oncotarget | volume = 7 | issue = 50 | pages = 82648-82657 | month = Dec | year = 2016 | doi = 10.18632/oncotarget.12244 | PMID = 27690341 }}</ref> |
|
| |
|
| ==Negative== | | ==Negative== |
| *[[Endocervical adenocarcinoma]].<ref name=pmid20335127>{{Cite journal | last1 = Hu | first1 = WW. | last2 = Tao | first2 = JH. | last3 = Li | first3 = GM. | last4 = Xu | first4 = X. | last5 = Yang | first5 = XM. | title = [Value of ER, VIM, CEA and p16 detection in the diagnosis and differential diagnosis of primary endocervical and endometrial adenocarcinomas]. | journal = Nan Fang Yi Ke Da Xue Xue Bao | volume = 30 | issue = 3 | pages = 526-8, 531 | month = Mar | year = 2010 | doi = | PMID = 20335127 }}</ref>
| |
|
| |
|
| ==See also== | | ==See also== |
Line 45: |
Line 37: |
| {{Reflist|1}} | | {{Reflist|1}} |
|
| |
|
| [[Category:Immunohistochemistry]] | | [[Category:Immunohistochemistry|Neuropathology]] |